Digital tool to be piloted to help transform and streamline the management of rheumatological and dermatological diseases, to ultimately improve patient care
By allowing for remote monitoring of patient-reported outcomes, the platform could help clinicians to prioritise appointments based on patient need, potentially saving time, addressing the current backlog1, and supporting the NHS recovery
Initial pilot projects could help drive digital transformation as part of the NHS Long Term Plan to support provision of faster, safer, and more convenient care2
Novartis and Cievert are committed to digital innovation, developing insights-led patient-focused solutions to support the NHS as it navigates the COVID-19 pandemic
London, UK, 26 March, 2021 — Novartis Pharmaceuticals UK Limited and Cievert Limited, a UK provider of innovative digital healthcare solutions, today announced a digital innovation partnership. The initiative aims to support patient care in rheumatology and dermatology by capturing patient-reported data and allowing clinicians to prioritise appointments on a needs-based model of care. The partnership was identified via the Novartis BIOME, with a selection procedure involving NHS clinicians and innovation leads. Novartis and Cievert are working closely with the NHS to launch pilot programmes at various sites across the UK.
Collaborating with patients and healthcare professionals (HCPs) across the UK, this digital platform aims to support patients, HCPs and the NHS in three areas:
Capturing patient digital health records in one single platform, which could reduce misalignment among healthcare teams, saving clinicians valuable time going between multiple systems and ultimately resulting in more timely management of care
Helping coordinate and prioritise appointments based on patient need rather than routinely scheduled reviews, which could help reduce waiting lists and hospital visits
Collecting real-time patient data in the community and helping patients to take more control over their health and care
By feeding patient-reported outcomes and disease activity measures into the platform, patients have the opportunity to be more involved in their care. Patients are encouraged to report symptoms and progress from home and between appointments, which can be remotely reviewed by clinical teams.
“In the current climate, the remote management of chronic disease is regularly navigated without supporting information from the patient regarding their condition. This creates a gap in our ability to understand the full picture of disease activity and progression in the outpatient setting,” said Dr Sandeep Bawa, Consultant Rheumatologist NHS Greater Glasgow and Clyde. “A remote monitoring solution that allows us to assess a patient’s disease activity in the community will allow us to manage a patient’s care more effectively, by identifying those in need of early clinical review from those who may require less frequent review. Now more than ever, digital tools have the potential to transform care for our patients and help streamline processes in the NHS by supporting the transition to a needs-based model of care, whilst maintaining best practice.”
“In this digital age, patients are increasingly looking to take a proactive role in their disease management. This is especially true for chronic diseases such as axial spondyloarthritis, which can affect everyone differently and has a large impact on daily activities – tailored management can make all the difference” said Dr Dale Webb, Chief Executive of the UK’s National Axial Spondyloarthritis Society (NASS). “We are thrilled that numerous patient groups and patients from across the UK have been involved in the development of this digital platform, providing key insights to help ensure the needs of patients are represented.”
Caitriona Walsh, Regional Partnership Business Unit Head, Novartis UK, commented, “As the UK marks a year since the start of the COVID-19 pandemic, the NHS is facing a large backlog of patient care. It is a core Novartis priority to invest in digital solutions to better support healthcare professionals by helping to prioritise patients which ultimately may increase NHS capacity and help save time. By partnering with Cievert we are applying the latest technology to support the NHS in its recovery.”
“In 5 years’ time we expect the existing clinical model of care to look markedly different,” said Cievert CEO and former NHS clinician, Chris Kennelly. “There is a unique opportunity to accelerate digital reform of the NHS after COVID-19, which has marked a shift in digital and remote healthcare access. Our partnership with Novartis is a big step in the right direction and we are looking forward to bringing our digital-first solution to HCPs and patients in the UK.”
Notes to Editors
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 130,000 people of nearly 150 nationalities work at Novartis around the world. Find out more at www.novartis.com.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. Since 2014, Novartis has invested over £200 million in R&D and is a leading sponsor of clinical trials, in the UK. For more information, please visit www.novartis.co.uk
About Cievert Cievert was founded in 2011 as a spin-out from the NHS in the North-East of England. Our goal is to make ‘routine healthcare a thing of the past’ – healthcare need is individual and we believe technology can help deliver personalised care that will support improved outcomes for patients whilst reducing costs for the NHS.
As a company, we work with NHS organisations across the UK and our software applications are in use across a range of clinical disciplines. One such discipline is radiotherapy, where our software currently supports close to 25% of all NHS cancer patients receiving this treatment, across the UK.
We invest heavily in research to improve patient outcomes and have a particular interest in clinical conditions that require long-term care. We are currently working with Durham University on the use of machine learning in healthcare to see whether we can identify clinical risk in patients, so that care can be better tailored to individual need. We are also working with the University of Sheffield and London South Bank University on projects to improve the long-term care of patients living with coeliac disease and patients living with a kidney transplant respectively.
About Novartis BIOME Founded in 2018, the Novartis BIOME is a catalyst for impactful collaboration. The BIOME brings together Novartis’ deep scientific experience with the expertise of the tech ecosystem to develop and scale digital solutions that improve and extend people’s lives. The BIOME allows internal and external teams to co-develop digital solutions alongside specific therapeutic offerings, research activities, and business processes within Novartis. Launched in 2020, striving to test and learn fast, the Novartis BIOME UK is located in the heart of London, focusing on scaling innovative solutions for chronic and long-term disease management.
UK | March 2021 | 114096
Novartis UK Media Relations Novartis UK Press Office Tel: 07771 541379 / 01276 698 691 E-mail: [email protected]
BMJ. Covid-19: Waiting times in England reach record highs. 2020; 370: m3557